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Viral protein U (Vpu) of HIV-1 has two known functions in replication of the virus: degradation of its cellular receptor
CD4 and enhancement of viral particle release. Vpu binds CD4 and simultaneously recruits the bTrCP subunit of the
SCF
bTrCP ubiquitin ligase complex through its constitutively phosphorylated DS52GXXS56 motif. In this process, Vpu was
found to escape degradation, while inhibiting the degradation of bTrCP natural targets such as b-catenin and IjBa.W e
further addressed this Vpu inhibitory function with respect to the degradation of Emi1 and Cdc25A, two bTrCP
substrates involved in cell-cycle progression. In the course of these experiments, we underscored the importance of a
novel phosphorylation site in Vpu. We show that, especially in cells arrested in early mitosis, Vpu undergoes
phosphorylation of the serine 61 residue, which lies adjacent to the bTrCP-binding motif. This phosphorylation event
triggers Vpu degradation by a bTrCP-independent process. Mutation of Vpu S61 in the HIV-1 provirus extends the half-
life of the protein and significantly increases the release of HIV-1 particles from HeLa cells. However, the S61
determinant of regulated Vpu turnover is highly conserved within HIV-1 isolates. Altogether, our results highlight a
mechanism where differential phosphorylation of Vpu determines its fate as an adaptor or as a substrate of distinct
ubiquitin ligases. Conservation of the Vpu degradation determinant, despite its negative effect on virion release,
argues for a role in overall HIV-1 fitness.
Citation: Estrabaud E, Le Rouzic E, Lopez-Verge `s S, Morel M, Belaı ¨douni N, et al. (2007) Regulated degradation of the HIV-1 Vpu protein through a bTrCP-independent
pathway limits the release of viral particles. PLoS Pathog 3(7): e104. doi:10.1371/journal.ppat.0030104
Introduction
The proteasome pathway ensures the degradation of
proteins that are marked by poly-ubiquitination. This process
is regulated by the E3 ubiquitin ligases that ensure the rate-
limiting step of substrate selection [1]. So far, three classes of
E3 ubiquitin ligases have been deﬁned, based on the presence
of a HECT, a Ring-H2-ﬁnger, and U-box domain, respectively.
Within the Ring-H2-ﬁnger family are the Skp1-Cullin1-F-box
proteins and the anaphase promoting complex/cyclosome
complexes, which are both involved in cell-cycle progression
[2]. The Skp1-Cullin1-F-box proteins display a modular
organization consisting of constant core subunits (Skp1,
Cullin1, Rbx1/Roc1) associated with a variable component,
the F-box protein [3,4]. The F-box protein binds Skp1
through its F-box motif and recruits the substrate through a
second domain. More than 70 F-box proteins have been
identiﬁed in humans, each member being responsible for the
degradation of a speciﬁc subset of proteins [5]. In most cases,
the binding of the F-box protein requires speciﬁc phosphor-
ylation of the substrate [6]. For example, bTrCP requires
phosphorylation of the serine residues present in the
consensus motif DSGUXS, which is found in most bTrCP
substrates. Phosphorylation of the bTrCP recognition motif
itself is often controlled by prior phosphorylation events of
the substrate protein, which allows a very tight control of the
degradation process [6,7].
Viruses have developed multiple ways to subvert cell
signaling pathways to replicate, disseminate, and escape from
the host immune system. The diversion of the ubiquitin-
mediated degradation machinery represents one such strat-
egy, which has been ﬁrst documented for the human
papillomavirus E6 protein [8]. Our earlier study of the
human HIV-1 viral protein U (Vpu) provided the ﬁrst
example reported for HIV-1 [9], and there is now a growing
list of proteins from various viruses that are reported to
induce the degradation of cellular targets [10,11].
Vpu is a small integral membrane protein encoded by HIV-
1 and a subset of related simian immunodeﬁciency viruses
and has no homolog in the less pathogenic HIV-2 virus
[12,13]. Recent studies in macaques using simian-HIV strains
have shown that Vpu plays an active role in the pathogenesis
[14]. Vpu performs two major functions in HIV-1 replication
[15]. First, Vpu enhances the release of retroviral particles
from most human cells, including lymphocytes and primary
macrophages [16–22]. This activity of Vpu, which is not
observed in simian cells, is suspected to reﬂect its ability to
counteract a host cell restriction factor speciﬁc for human
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channel TASK-1 [26]. Second, Vpu induces the degradation of
the CD4 viral receptor and therefore participates in the
general downregulation of CD4 expression during the course
of HIV infection [27]. Vpu-mediated CD4 degradation is
thought to prevent CD4-Env binding in the endoplasmic
reticulum in order to facilitate proper Env assembly into
virions [28,29]. We earlier reported the cloning and the
characterization of bTrCP as a Vpu cell partner that the viral
protein connects to CD4 to induce its degradation [9].
Interaction between bTrCP and Vpu, which controls the
subsequent CD4 degradation, depends on the phosphoryla-
tion of serines 52 and 56 of Vpu within its DSGUXS bTrCP
recognition motif [9,30]. In addition, the sequestration of
bTrCP by Vpu has been shown to induce the stabilization of
the bTrCP substrates, b-catenin and IjBa [31,32].
We and others have previously observed that Vpu remains
stable during the course of CD4 degradation [9,33]. Here we
report the unexpected ﬁnding that Vpu is subjected to
proteasome-mediated degradation in cells arrested in early
mitosis by nocodazole. We further show that this degradation
process requires phosphorylation of the serine 61 residue
adjacent to the bTrCP-binding motif. Therefore, differential
phosphorylation of Vpu determines its fate as an adaptor or
as a substrate of distinct ubiquitin ligases. The controlled
degradation of Vpu, which is not mediated by bTrCP,
decreases the efﬁciency of Vpu-mediated release of HIV-1
virions. It may thus contribute to the balance between
efﬁcient HIV-1 dissemination and preservation of the
reservoir of infected cells.
Results
Vpu Stabilizes Cdc25A but Has No Effect on Emi1, Despite
That Both Cellular Proteins Are bTrCP Substrates Involved
in Cell-Cycle Progression
It has been well documented that sequestration of bTrCP
by Vpu strongly inhibits the degradation of b-catenin and
IjBa [31,32]. We investigated whether Vpu also inhibited the
degradation of the cell-cycle regulators, Cdc25A and Emi1,
whose degradation occurs via a bTrCP-dependent pathway in
the S and pro-metaphase steps of the cell cycle, respectively
[34–37]. In a ﬁrst set of experiments, we used an expression
construct encoding Vpu fused at its carboxyterminus to a
HA-green ﬂuorescent protein (GFP) tag that provided more
sensitive and speciﬁc detection than the untagged viral
protein chimera. This protein is fully functional regarding
the two activities of Vpu, enhancement of particles release
and CD4 degradation (Figure S1 and Text S1). As shown in
Figure 1A, Myc-Emi1 was readily degraded in Hela cells
arrested in early mitosis by nocodazole treatment as
compared to asynchronous cells (anti-Myc panel, compare
lane 3 to 7). Coexpression of Vpu did not increase the
expression of Myc-Emi1 in nonsynchronized cells nor did it
restore a detectable level of Myc-Emi1 in nocodazole-treated
cells (Figure 1A, anti-Myc panel, compare lane 3 to 4 and lane
7 to 8). In contrast, Vpu increased the expression of
endogenous b-catenin used as a control (compare lane 1 to
2 and lane 5 to 6). Conﬁrming the lack of effect of Vpu on
Emi1 accumulation, Vpu was unable to signiﬁcantly stabilize
endogenous Emi1, either in asynchronous or in nocodazole-
treated cells (Figure 1B, anti-Emi1 panel, compare lane 1 to 3
or lane 2 to 4). Whether this lack of effect was speciﬁc for
Emi1 was addressed by monitoring the accumulation of
Cdc25A under the same experimental conditions. Cd525A
accumulated in cells arrested in early mitosis by nocodazole
treatment, as previously observed [35], and Vpu expression
further increased this accumulation (Figure 1B, anti-Cdc25A
panel, compare lane 1 to 2 and lanes 3 and 4). Taken together,
these results indicate that Vpu differentially affects bTrCP-
mediated degradation events, which occur at different phases
of the cell cycle. As a possible explanation for these intriguing
observations, the amount of Vpu itself varied depending on
cycle progression since expression of Vpu was reduced in
nocodazole-treated cells (Figure 1A, anti-HA panel, compare
lane 2 to 6 and lane 4 to 8 and Figure 1B compare lane 3 to 4).
Vpu Is Targeted by the Ubiquitin-Proteasome Pathway in
Nocodazole-Treated Cells
Based on previous pulse chase experiments, Vpu remains
stable during the 1-h time course used to monitor Vpu-
mediated CD4 degradation [33]. However, we observed in the
present study that inhibition of proteasome activity by
MG132 strongly increased the amount of Vpu in nocoda-
zole-treated cells (Figure 2A, compare lane 4 to 6). Vpu
expression was not affected by a shorter treatment with
nocodazole used to disrupt the microtubule network without
arresting cells in early mitosis (Figure 2B, compare lane 1 to
3). The efﬁciency of this short nocodazole treatment was
checked by immunoﬂuroescence using anti-a-tubulin anti-
bodies (unpublished data). Vpu was previously shown to
reside in the reticulum and the Golgi compartments and
more recently in the recycling endosomes [25,38]. Since Golgi
compartments undergo a profound redistribution during
mitosis, we next asked whether decreased Vpu expression
merely resulted from this disassembly process. Vpu amounts
remained unchanged following treatment with brefeldin A,
which promoted Golgi disassembly, as checked by immuno-
ﬂuorescence with an anti-rab6 antibody (Figure 2B, compare
lane 1 to 4; unpublished data). Altogether, these results
suggest that the mitotic arrest triggered by nocodazole, rather
than an indirect effect induced by microtubules or Golgi-
targeting drugs, was responsible for Vpu-induced degrada-
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Author Summary
In addition to the structural and catalytic proteins characteristic of
retroviruses, HIV-1 encodes auxiliary proteins that govern virus-host
interaction. One such auxiliary protein termed Vpu both enhances
virion release from human cells and the degradation of CD4, the
cellular surface receptor of HIV-1. The latter activity relies on a
strategy frequently used by pathogens, i.e., the hijacking of the
protein degradation machinery. This process involves the ubiquitin
ligases that ensure the selection of the protein subsequently
degraded. Vpu interacts both with an ubiquitin ligase and CD4,
bridging the latter to the degradation machinery. Here, we show
that in addition to subverting one particular ubiquitin ligase to
trigger CD4 degradation, Vpu is itself recognized in a phosphor-
ylation-dependent manner by a distinct ubiquitin ligase and
degraded. Mutations of Vpu that confer resistance to this
degradation process enhance viral particle release, whereas the
determinant of Vpu turnover is paradoxically well conserved among
HIV-1 isolates. These results suggest that the virus is constrained to
limit its own production for long-term persistence.tion via a proteasome-dependent pathway. Furthermore,
Vpu-HA-GFP was not detectable in mitotic cells by ﬂuo-
rescence microscopy, in contrast to the control RE-GFP
protein expressed in the endoplasmic reticulum compart-
ment (Figure S2).
We next addressed whether bTrCP was involved in Vpu
degradation using a Vpu mutant defective in bTrCP binding
due to the substitution of the serine residues 52 and 56 in the
bTrCP recognition motif (Vpu2/6). As shown in Figure 2C, the
pools of wild-type and mutant Vpu were decreased to a
similar extent by nocodazole-induced mitotic arrest. That
Vpu2/6 underwent degradation in early mitosis suggested that
bTrCP is not responsible for Vpu degradation.
Reduction of Vpu expression in nocodazole-treated cells
was further conﬁrmed with the untagged Vpu protein
expressed from the HIV-1 pNL4–3 provirus both by western
blot (Figure 2D) and by immunoﬂuorescence (Figure 2E). In
the latter experiment, anti-Gag labeling identiﬁed infected
cells, and DAPI staining was used to distinguish interphasic
from mitotic cells. As shown in Figure 2E, Vpu was readily
detected in interphasic cells by a perinuclear staining (cells 3
and 4) whereas no signal was observed in mitotic cells (cells 1
and 2).
Identification of a New Phosphorylation Determinant in
Vpu Involved in the Viral Protein Turnover
A slow migrating form of Vpu and of Vpu2/6 was apparent
when lysates from nocodazole-treated cells were subjected to
extended electrophoresis (Figure 3B, arrows). Treatment with
alkaline phosphatase of Vpu and Vpu2/6 immunoprecipitates
from mitotic cell extracts suppressed the slow migrating Vpu
species (Figure S3). This indicated that a new phosphoryla-
tion event of Vpu was taking place in mitosis. We individually
mutated the three potential phosphorylation sites present in
Vpu outside of the bTrCP recognition motif, i.e., S23, Y29,
and S61 (Figure 3A). Substitution of serine 61 into alanine
within the Vpu2/6 mutant precluded the appearance of the
slow migrating form seen in nocodazole-treated cells, whereas
mutations of S23 and Y29 had no effect (Figure 3C, lanes 5–8).
Mutation of serine 61 in the context of wild-type Vpu led to
identical results (unpublished data).
We hypothesized that Vpu phosphorylation on serine 61
provided the signal that triggered Vpu degradation in mitotic
cells. In support of this hypothesis, the Vpu S61A mutant
strongly accumulated in cells as compared to the wild-type
protein (Figure 3D, compare lane 2 to 4). In addition, Vpu
S61A coimmunoprecipitated very efﬁciently with endoge-
nous bTrCP (Figure 3D, ﬁrst panel, lane 4), and accordingly,
strongly stabilized b-catenin (Figure 3D, second panel, lane 4).
As expected, Vpu2/6, used as a control, did not interact with
bTrCP and did not stabilize b-catenin (Figure 3D, lane 3).
These results were further conﬁrmed in the context of the
HIV-1 NL4–3 virus. To avoid a change in the viral envelope
overlapping sequence, the Vpu serine 61 was changed into a
glutamine. Introduction of Vpu S61Q mutation in the NL4–3
provirus extended the half-life of the Vpu protein; whereas,
as previously reported [33], S52A and S56A mutations hardly
affected the degradation rate of the protein (Figure 4A and
4B). Consistent with our previous observations, interaction
with bTrCP was not affected by the S61Q mutation (Figure
4C, lane 3). Altogether, these results support the conclusion
that degradation of Vpu occurs via a bTrCP-independent
Figure 1. Vpu Is Degraded in Nocodazole-Treated Cells
(A) Vpu does not affect Emi1 expression. HeLa cells were mock-
transfected (lanes 1 and 5), or transfected with Vpu-HA-GFP alone (lanes
2 and 6), Myc-Emi 1 alone (lanes 3 and 7), or cotransfected with Vpu-HA-
GFP and Myc-Emi1 (lanes 4 and 8). 24 h after transfection cells were
treated 18 h with nocodazole (lanes 5–8) or DMSO (lanes 1–4). Cell
lysates were separated by SDS-PAGE and analyzed by western blot using
the indicated antibodies.
(B) Cdc25A is stabilized in the presence of Vpu. HeLa cells expressing
Vpu-HA-GFP (lanes 3 and 4) or not (lanes 1 and 2) were treated as in
Figure 1A with nocodazole (lanes 2 and 4) or with DMSO alone (lanes 1
and 3). Cell lysates were separated by SDS-PAGE and analysed by
western blot using the indicated antibodies. Anti-cyclin A and anti-cyclin
B antibodies were used to control the efficiency of nocodazole treatment
under which cyclin A but not cyclin B is degraded.
doi:10.1371/journal.ppat.0030104.g001
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bTrCP Activity
(A) Vpu degradation occurs via the proteasome pathway.
HeLa cells either mock-transfected (lanes 1, 3, and 5) or expressing Vpu-HA-GFP (lanes 2, 4, and 6) were left untreated or treated for 18 h with
nocodazole (lanes 3–6). Where indicated, MG132 was added 6 h prior to harvest of cells. Cell lysates were analyzed by western blot using the indicated
antibodies.
(B) Vpu expression is not sensitive to brefeldin A or to short nocodazole treatments.
HeLa cells expressing Vpu-HA-GFP were treated with nocodazole during either 18 h (lane 2) or 2.5 h (lane 3) and with BFA during 1.5 h (lane 4) or DMSO
alone (lane 1). Cell lysates were separated by SDS-PAGE and analyzed by western blot using the indicated antibodies.
(C) Degradadion of Vpu in nocodazole-treated cells does not require a functional bTrCP-binding site.
HeLa cells were transfected with the expression vectors encoding either wild-type Vpu-HA-GFP (lanes 1 and 3) or the Vpu 2/6-HA-GFP mutant defective
in bTrCP binding (lanes 2 and 4), together with a plasmid expressing Myc-bgalactosidase used as an internal reporter. Cells were left untreated or
treated 18 h with nocodazole as indicated. Vpu-HA-GFP and Myc-bgalactosidase were revealed by western blot using anti-Vpu and anti-myc antibodies,
respectively. The histogram represents the Vpu/bgalactosidase ratios, calculated from the respective quantified signals.
(D) Vpu expression from the HIV-1 provirus is reduced in nocodazole-treated cells. HeLa cells were transfected with pNL4–3DVpr provirus together with
a plasmid expressing GFP used as an internal control. Cells were treated with nocodazole where indicated. Vpu was detected by western blot using anti-
Vpu antibodies.
(E) Vpu is not detectable in infected mitotic cells.
HeLa cells were transfected by the pNL4–3 provirus. 48 h after transfection, cells were fixed and analyzed by immunofluorescence using anti-Gag and
anti-Vpu antibodies. DNA was revealed by DAPI staining. Arrows 1 and 2 indicate mitotic cells and arrows 3 and 4 indicate interphasic cells.
wt, wild-type.
doi:10.1371/journal.ppat.0030104.g002
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residue.
Mutation of Vpu Serine 61 Enhances the Release of HIV-1
Particles
Vpu-mediated CD4 degradation was not affected by
mutation of Vpu serine 61 (unpublished data) as was expected
from the preserved interaction of the mutant with bTrCP
(Figures 3D and 4C). We therefore investigated whether this
mutation affected the other known Vpu activity, namely, the
enhancement of viral particle release that we assayed by
monitoring the extracellular content in mature p24 capsid.
As shown in Figure 5A, HIV-1 encoding the S61 Vpu mutant
was released much more abundantly from HeLa cells than the
wild-type virus. As reported previously, S52A and S56A
mutations of Vpu had no effect on virus release whereas the
Figure 3. Identification of a New Phosphorylation Determinant in Vpu
(A) Schematic representation of the Vpu sequence from the HIV-1 NL4–3 strain. Potential phosphorylation residues are indicated in bold. These include
two serine residues (S23 and S61) and one tyrosine (Y29), in addition to the S52 and S56 present in the boxed bTrCP-binding motif.
(B) A new form of Vpu and Vpu 2/6 is detected in nocodazole-treated cells. HeLa cells were mock-transfected (lanes 1 and 4), transfected by Vpu-HA-
GFP (lanes 2 and 5), or by Vpu 2/6-HA-GFP (lanes 3 and 6). 24 h after transfection, cells were treated 18 h with nocodazole (lanes 4–6) or with DMSO
(lanes 1–3). Cell lysates were separated by SDS-PAGE and analyzed by western blot using the indicated antibodies.
(C) Vpu is phosphorylated on serine 61 in nocodazole-treated cells.
HeLa cells were transfected with the indicated Vpu variants: Vpu2/6-HA-GFP (lanes 1 and 5), Vpu2/6 S61A (lanes 2 and 6), Vpu 2/6 S23A (lanes 3 and 7),
and Vpu 2/6 Y29F (lanes 4 and 8). Cells were treated during 18 h with nocodazole (lanes 5–8) or with DMSO (lanes 1–4). Cell lysates were separated by
SDS-PAGE and analyzed by western blot using the indicated antibodies.
(D) VpuS61A conserves its ability to interact with bTrCP.
Lysates from HeLa cells expressing Vpu-HA-GFP (lanes 1 and 2), Vpu 2/6-HA-GFP (lane 3), or Vpu S61A-HA-GFP (lane 4) were immunoprecipitated with
anti-bTrCP (IP TrCP, lanes 2–4) or with control antibodies (IP C, lane 1). Immunoprecipitates and cell lysates were separated by SDS-PAGE and analyzed
by western blot using the indicated antibodies.
doi:10.1371/journal.ppat.0030104.g003
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Quantitative analysis of the ratio of released capsid protein
over total amount of capsid indicated that the S61Q Vpu
mutant increased the viral release process rather than the
expression of the viral capsid (Figure 5B). To assess the
speciﬁcity of these effects with respect to the human-
restricted activity of Vpu, we further studied HIV-1 particle
release from African green monkey Cos 7 cells, where Vpu
has been shown to be dispensable for efﬁcient virion release
[19,24]. Wild-type and Vpu-mutated HIV-1 were released
from these cells with similar efﬁciencies (Figure 5C). We
further analyzed the infectivity of the viral particles from
HeLa cell supernatants (from experiment 5A). Vpu S61
mutation did not affect the infectivity of the viral particles
(Figure 5D). Altogether, these results indicate that HIV-1
particle release is increased when the Vpu degradation
process is impaired by the mutation of serine 61.
Discussion
The major ﬁnding of our study is the identiﬁcation of a
new phosphorylation determinant in the HIV-1 Vpu protein,
which controls the efﬁciency of HIV-1 particle release by
regulating the turnover of the viral protein.
Vpu Inhibitory Function of the SCF
bTrCP E3 Ubiquitin
Ligase
Our initial goal was to study the potentially adverse effects
of Vpu expression on the timely regulated degradation of
bTrCP substrates involved in cell-cycle progression. To our
surprise, Emi1 escaped the Vpu-mediated stabilization
observed for the constitutively degraded bTrCP substrate,
b-catenin, and for the cell-cycle regulator Cdc25A, normally
degraded during the S phase. This paradox may be reconciled
by our further demonstration of a regulated degradation
process of Vpu itself, which predominantly occurs in early
mitosis. Indeed, one simple explanation is that the pool of
Vpu drops before the cell cycle reaches the phase where Emi1
degradation takes place, namely at the G2-M transition.
Another nonexclusive possibility is the existence of a bTrCP
pool dedicated to Emi1 degradation [39], which is non-
accessible to Vpu.
Vpu as an Adaptor or a Substrate of E3 Ubiquitin Ligases
We have shown that the phosphorylation of Vpu serine 61,
which lies adjacent to the bTrCP recognition motif, is the
triggering event for subsequent Vpu degradation. Accord-
ingly, mutation of Vpu serine 61 into a non-phosphorylable
residue stabilized Vpu, expressed either alone or in the
context of the HIV-1. Two lines of evidence indicate that Vpu
degradation occurs via a bTrCP-independent pathway: (i) The
Vpu mutant, which fails to recruit bTrCP due to substitutions
in its binding motif, was degraded in mitosis-arrested cells to
the same extent as the wild-type protein; (ii) conversely, the
S61 Vpu mutant, which still binds bTrCP, showed a much
slower turnover than the wild-type protein. In turn, this
implies that Vpu is recognized as a substrate by an E3
ubiquitin ligase other than bTrCP, as illustrated in the model
presented in Figure 6. Vpu has been shown to be constitutively
phosphorylated by casein kinase II on serine 52 and serine 56
of the bTrCP-binding motif [40]. As a result, Vpu binds bTrCP
and acts as an adaptor between the SCF
bTrCP and CD4, leading
to the degradation of the HIV-1 receptor [9]. In contrast, the
new phosphorylation event underscored here, which takes
place on the serine 61, creates a binding site for an E3
ubiquitin ligase, which in turn targets Vpu for proteasome-
mediated degradation. Phosphorylation of the serine 61
residue does not depend on prior phosphorylation of the
bTrCP-binding motif since it still occurs when residues 52 and
56 are mutated. However, binding to the two E3 ubiquitin
ligases might be mutually exclusive, considering the proximity
between their respective binding sites. How the viral protein
escapes the degradation via the SCF
bTrCP ubiquitin ligase
while it is recognized as a substrate by a second ubiquitin
Figure 4. Mutation of Vpu S61 in the HIV-1 Virus Markedly Extends the
Viral Protein Half-Life While Preserving Its Interaction with bTrCP
(A) HeLa cells were transfected with 0.5 lg of HIV-1 proviral DNA
corresponding to pNL4–3 wild-type, pNL4–3 Vpu 2/6, or pNL4–3 Vpu
S61Q together with 0.05 lg of GFP expression vector used as a control
for the transfection. Cells were treated with cycloheximide and harvested
at the indicated time points. Cell lysates were separated by SDS-PAGE
and analyzed by western blot for GFP and Vpu expression.
(B) Quantification of Vpu expression shown in (A). After quantification,
the signals obtained in (A) were used to calculate the Vpu/GFP
expression ratios at the indicated time points after cycloheximide
addition.
(C) The S61 Vpu mutant conserves binding to bTrCP in cells transfected
with HIV-1 proviral DNAs.
HeLa cells were transfected with 0.5 lg of HIV-1 proviral DNAs encoding
the indicated Vpu proteins. Cell lysates were immunoprecipitated with
anti-bTrCP antibodies and analyzed for Vpu expression (top) or directly
analyzed with Vpu antibodies (bottom).
doi:10.1371/journal.ppat.0030104.g004
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such an issue holds for other viral proteins that subvert E3
ubiquitin ligases. For example, HPV E6 and E7 proteins show
the same dual fate as Vpu: they act as adaptors of an E3
ubiquitin ligase to direct the abnormal degradation of a
cellular protein for the beneﬁt of the virus [11] and as
substrates of a probably distinct E3 ubiquitin ligase [41–44]. In
the same line, the HIV-1 Vpr protein, which recruits the
DDB1-Cul4A E3 ubiquitin ligase to induce cell-cycle arrest as
shown in our recent study [45], appears to be stabilized when
incorporated in this complex (unpublished data).
Limiting the Release of Viral Particles
We show here that the slower turnover of Vpu resulting
from S61 substitution increases the release of HIV-1 virions,
hence suggesting a selective advantage. This prompted us to
examine the degree of conservation of the corresponding
Vpu residue among HIV-1 isolates. To address this point, we
took advantage of the previous analysis performed by
McCormick-Davis and coworkers (2000) on the Vpu sequen-
ces from 100 strains of HIV-1 group M from diverse
geographical regions [46]. Remarkably, 77% of these strains
showed a serine residue, either at position 61 or at position
64, i.e., 4 and 7 residues downstream of the bTrCP-binding
motif (Figure 6B and unpublished data). Of note, this spacing
difference corresponds to one helix turn, which suggests that
the relevant serine residue is presented on the same face of
the Vpu a-helix. This indicates that within the M group of
HIV-1, the evolutionary trend is toward the conservation of a
regulated Vpu degradation process. HIV-1 replicates in both
quiescent and dividing cells. In the latter, it might be
advantageous for the virus to ﬁne-tune virion production
according to cell-cycle progression. This may in turn reﬂect
that long-term persistence of the virus requires the optimal
balance between efﬁcient viral production and host cell
viability. In light of our present study, the regulated
degradation process of Vpu is expected to be lost in the
viral strains naturally mutated at the relevant phosphoryla-
tion site. Whether these strains show higher pathogenicity
will be interesting to address for our better understanding of
the constraints that govern the relation between HIV-1 and
the human organism.
Materials and Methods
Plasmid constructs. pcDNA3 Vpu-HA-GFP and Vpu2/6-HA-GFP
were described in Besnard-Guerin et al., 2004 [32]. Mutations of S23,
S61, and Y29 in pcDNA3 Vpu-HA-GFP and pcDNA3 Vpu2/6-HA-GFP
were introduced by site-directed mutagenesis with Pfu Turbo
polymerase (Stratagene, http://www.stratagene.com/) using the follow-
ing set of forward primers where substituted codons are underlined:
Vpu S23A: 59-GCAATAGTTGTGTGGGCCATAGTAATCATAG-39;
Vpu Y29A: 59-CCATAGTAATCATAGAATTTAGGAAAATATTAA
GAC-39;V p uS 6 1 A :5 9-GAGAGTGAAGGAGAAATAGCAG
CACTTGTGGAGATGG-39).
Proviral DNAs. The pNL4–3 HIV1 clones as well as its Vpu- or Vpr-
deﬁcient derivative were gifts from Dr. K. Strebel. Mutations of the
vpu gene were done using a pUC19 shuttle vector containing the Eco
RI-Nhe I fragment (5743–7251 [47]) by directed mutagenesis with Pfu
Turbo polymerase (Stratagene). Vpu2/6 and Vpu S61 variants were
created using the following set of forward primers, where substituted
codons are underlined: Vpu2/6: 59-GAAAGAGCAGAAGACAATGG
CAATGAGAATGAAGGAGAAGTA-39; VpuS61:59- GAGTGAAGGA
GAAGTACAAGCACTTGTGGAGATG-39.
All constructs were veriﬁed by nucleotide sequencing with a
DYEnamic ET Terminator kit (Amersham, http://www.gehealthcare.
com/) and a Genetic Analyzer (Applied Biosystems, http://www.
appliedbiosystems.com/).
Cell culture, transfection procedures, and treatments. HeLa, P4R5
MAGI cells, and Cos 7 cells were maintained in DMEM supplemented
Figure 5. Release of HIV-1 Particles Is Enhanced by Vpu S61 Mutation
(A) Vpu S61 mutation enhances HIV-1 release from the Vpu-sensitive HeLa cells. HeLa cells were transfected with 0.5 lg of the indicated HIV-1 proviral
DNAs. Capsid p24 antigen was quantified in culture cell supernatants 24 and 48 h after transfection.
(B) The tranfected cells described in (A) were lyzed 48 h post-transfection and analyzed for their capsid p24 content. The graph represents the ratios of
released p24 released over total p24 amount (released þ internal), 48 h post-transfection.
(C) Vpu S61 mutation has no effect on HIV-1 release from the Vpu-insensitive Cos 7 cells. Release was studied in Cos 7 cells as indicated in (A).
(D) Vpu S61 mutation does not alter HIV-1 infectivity. The indicated viruses were produced in Hela cells (A) and their infectivity was assayed in Magi
cells. Results are expressed as the ratios of infectious particles in Magi cells per ng of p24 capsid protein in the input virus.
doi:10.1371/journal.ppat.0030104.g005
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HIV-1 Vpu Adaptor or Substrate of Ub E3with glutamine and 10% fetal calf serum. Plasmid transfections were
performed using Fugene 6 reagent (Roche, http://www.roche.com/).
Nocodazole (Sigma, http://www.sigmaaldrich.com/) was used at the
ﬁnal concentration of 450 ng/ml. Brefeldin A (Calbiochem, http://
www.calbiochem.com/) was used at 5 lM during 1.5 h. Cells were
treated with MG132 (Sigma) at 20 lM during 6 h.
Immunoprecipitation, western blot procedures, and antibodies.
Cells grown in 10-cm dishes were lysed in SD buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 0.5% Triton X100) for 30 min at 4 8C. Cell
lysates were clariﬁed by centrifugation and incubated with primary
antibodies for 2 h at 4 8C or overnight using anti-bTrCP antibodies.
Protein G-sepharose from Sigma (20 ll of 50% slurry in SD buffer)
was added and the samples were further rocked at 4 8C for 30 min.
After four washes in lysis buffer, immunoprecipated proteins were
recovered by incubation in Laemmli buffer (Sigma) at 95 8C for 5 min
and separated by SDS-PAGE electrophoresis. Following transfer onto
PVDF membranes, proteins were revealed by immunoblot analysis
using a chemiluminescent procedure (ECL, GE Healthcare, http://
www.gehealthcare.com/). Signals were acquired by a LAS-3000
apparatus (Fujiﬁlm, http://www.fujiﬁlm.com/) for further quantiﬁca-
tion, using the provided software Multigauge. Monoclonal antibodies
directed at the HA (3F10) and MYC (9E10) and GFP tags were
obtained from Roche. Anti-actin (I-19), anti-cyclin A (H-432), anti-
cyclin B1 (H-433), and monoclonal anti-Cdc25A (F-6) were purchased
from Santa Cruz Biotechnology (http://www.scbt.com/); monoclonal
anti-b-catenin was obtained from Transduction Laboratories (http://
www.bdbiosciences.com/). Anti-Vpu was puriﬁed from the antiserum
(NIH 969) as described below. Anti-bTrCP and anti-Emi1 are gifts
from K. Strebel and P. Jackson, respectively. The p24 HIV-1 capsid
protein was revealed using a rabbit anti-p24 polyclonal antibody
(ARP366, National Institute for Biological Standards and Control,
Hertfordshire, United Kingdom).
Puriﬁcation of Vpu antiserum. Recombinant GST fused to the
cytoplasmic domain of Vpu was separated by SDS-PAGE electro-
phoresis. Following transfer onto PVDF membrane, the Vpu
antiserum (NIH 969) was incubated with the membrane in TBS
buffer (50 mM Tris, 150 mM NaCl) containing 0.05% Tween 20 and
5% milk overnight at 4 8C. After four washes in TBS 0.05% Tween,
the membrane was incubated 10 min at 4 8C in PBS. The puriﬁed
antibodies were eluted in 0.2 M glycine/HCl buffer at room temper-
ature. The acidic pH was neutralized by adding 2 M Tris.
Immunoﬂuorescence assays. For p24 capsid and Vpu staining,
HeLa cells were seeded in 6-well plates onto glass cover slips at a
density of 2310
5 cells/well, and transfected with 1 lg of pNL4–3. 48 h
Figure 6. Model for Vpu Degradation
(A) Vpu as an adaptor of the SCF
bTrCP complex or as a substrate targeted to the proteasome via a bTrCP-independent pathway. Vpu is constitutively
phosphorylated on the serine 52 and 56 residues present in the bTrCP-binding site. Phosphorylation of these serines is essential for Vpu binding to
bTrCP and for CD4 degradation. By bridging bTrCP, a subunit of the SCF
bTrCP complex to CD4, Vpu induces proteasome-mediated degradation of CD4.
In this case, Vpu acts as an adaptor of the bTrCP complex, now able to target CD4. Here, we underscore an additional phosphorylation event taking
place at the S61 residue. This phosphorylation site is critical for Vpu turnover and for the control of virus release. In this other setting, Vpu behavesa sa
substrate of an E3 ubiquitin ligase distinct from the bTrCP complex.
(B) The determinant of regulated Vpu turnover is highly conserved within HIV-1 isolates. Among the Vpu sequences from 100 strains of HIV-1 group M
analyzed by McCormick-Davis and coworkers (2000) [46], 77% show a serine residue, either at position 61 or at position 64, i.e., 4 and 7 residues
downstream of the bTrCP-binding motif (in the rectangle). In addition, this serine is always preceded by the EI or EL di-residue. Only six representative
Vpu sequences have been chosen in our alignment to highlight this conservation. ‘‘ ’’, aa identical to HIVHXB2 and ‘‘.’’, gaps introduced for optimal
alignment of sequences.
doi:10.1371/journal.ppat.0030104.g006
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paraformaldehyde, quenched for 10 min in PBS /0.1 M glycine, and
then permeabilized for 10 min in IF buffer (PBS, BSA 1 mg/ml, 0.01%
Triton X100). Cells were then incubated with puriﬁed anti-Vpu
(1:500) and anti-p24 capsid (25A Hybridolab, 1:500, http://www.
pasteur.fr/) antibodies during 1 h, washed in IF buffer, and incubated
for 30 min with Cya2-labeled anti-rabbit (1:300) and Cya3-labeled
(1:750) anti-mouse antibodies (Jackson ImmunoResearch, http://www.
jacksonimmuno.com/). After washes in IF buffer and mounting in
medium containing DAPI (Vectashield, http://www.vectorlabs.com/),
cells were examined by direct ﬂuorescent microscopy.
HIV-1 production assay. HeLa and Cos 7 cells (2 3 10
5 cells) were
transfected with 0.5 lg of different pNL4–3 proviral plasmids (wild-
type, DVpu, Vpu 2/6, Vpu61) using Fugene 6 reagent (Roche). Cell
supernatants were collected 24 and 48 h post-transfection and
quantiﬁed for HIV-1 p24 antigen using an HIV-1 p24 antigen assay
(Beckman Coulter, http://www.beckmancoulter.com/). Cell superna-
tants harvested 48 h post-transfection were also used to infect P4R5
Magi indicator cells. Protein cell lysates were separated by SDS/PAGE
and analyzed by western blot.
Supporting Information
Figure S1. Vpu-HA-GFP Is Functional Regarding the Two Main
Activities of Vpu
(A) Vpu-HA-GFP enhances viral particle release. HeLa cells were
transfected with 0.5 lg of HIV-1 proviral DNAs (wild-type or DVpu)
and 0.2 lg of Vpu-HA-GFP expressing vector (or the corresponding
empty vector) where indicated. p24 antigen was quantiﬁed in culture
cell supernatants 24 and 48 h after transfection.
(B) Vpu-HA-GFP downregulates CD4 expression.
P4–2 cells were transfected with Vpu-HA-GFP or Vpu 2/6-HA-GFP.
Cells were analyzed by FACS for the expression of both CD4 and Vpu.
After transfection of Vpu-HA-GFP, 46.1% (23 þ 23.1) of the cells
express Vpu; half of them are CD4-negative (FACS panel, left).
Therefore, about 50% of the cells expressing Vpu are CD4-negative
(see histogram). After transfection of Vpu2/6-HA-GFP, 49% (46.2 þ
2.8) of the cells do express Vpu; 2.8% of them are CD4-negative
(FACS panel, right). Therefore, about 5.7% of the cells expressing
Vpu2/6-HA-GFP are CD4-negative (see histogram). Expression of
both Vpu-HA-GFP and Vpu2/6-HA-GFP was checked by western blot.
Found at doi:10.1371/journal.ppat.0030104.sg001 (54 KB PDF).
Figure S2. Vpu-HA-GFP Is Not Detected in Mitotic Cells
HeLa cells were transfected with Vpu-HA-GFP or the control RE-GFP
protein expressed in endoplasmic reticulum compartment. 36 h after
transfection, cells were ﬁxed and analyzed by ﬂuorescence. DNA was
revealed by staining with DAPI. Stars indicate cells in mitosis.
Found at doi:10.1371/journal.ppat.0030104.sg002 (86 KB PDF).
Figure S3. Vpu Is Phosphorylated Outside the DSGXXS Motif
HeLa cells were mock-transfected (lanes 1 and 6), transfected with
Vpu-HA-GFP (lanes 2, 3, 7, 8), or with Vpu 2/6-HA-GFP (lanes 4, 5, 9,
10). 24 h after transfection, cells were treated with nocadazole (lanes
6–10) or DMSO alone (lanes 1–5) during 18 h. Cell lysates were
immunoprecipitated using an anti-HA antibody. Immunoprecipitates
were left untreated (lanes 1, 2, 4, 6, 7, and 9) or treated with alkaline
phosphatase (lanes 3, 5, 8, and 10) and analyzed by western blot using
anti-GFP antibodies.
Found at doi:10.1371/journal.ppat.0030104.sg003 (53 KB PDF).
Text S1. Supplementary Materials and Methods
Found at doi:10.1371/journal.ppat.0030104.sd001 (20 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
bers for the proteins and genes studied here are EMI1 (NM_012177)
and HIV-1 molecular clone pNL4–3 (AF324493).
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